CompletedPhase 2NCT03488524
Open Label Extension Study of AMX0035 in Patients With ALS
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amylyx Pharmaceuticals Inc.
- Principal Investigator
- Sabrina Paganoni, MD, PhDMassachusetts General Hospital
- Intervention
- AMX0035(drug)
- Enrollment
- 90 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2021
Study locations (24)
- Barrow Neurological Institute-Dignity Health, St Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- University of California, Irvine, Orange, California, United States
- California Pacific Medical Center, San Francisco, California, United States
- University of Florida College of Medicine, Gainesville, Florida, United States
- University of South Florida College of Medicine, Tampa, Florida, United States
- Emory University Hospital, Atlanta, Georgia, United States
- University of Iowa, Carver College of Medicine, Iowa City, Iowa, United States
- University of Kentucky Medical Center, Lexington, Kentucky, United States
- Ochsner Neuroscience Institute, New Orleans, Louisiana, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
- University of Michigan, Michigan Medicine, Ann Arbor, Michigan, United States
- Hennepin County Medical Center, Minneapolis, Minnesota, United States
- Washington University Medical Center, St Louis, Missouri, United States
- +9 more locations on ClinicalTrials.gov
Collaborators
Massachusetts General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03488524 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)